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Abstract
Introduction The 'MINO' (mammary intraepithelial neoplasia
outgrowth) mouse model of ductal carcinoma in situ (DCIS)
consists of six lines with distinct morphologic phenotypes and
behavior, each meeting experimentally defined criteria for
'precancer'. Specifically, these lines grow orthotopically in
cleared mammary fat pads and consistently progress to an
invasive phenotype that is capable of ectopic growth. Transition
to carcinoma has a consistent latency for each line, and three of
the lines also exhibit pulmonary metastatic potential.
Methods Gland cleared orthotopic transplanted precancer
MINO tissues were analyzed by bacterial artifical chromosome
and oligo array comparative genomic hybridization,
microsatellite PCR, and telomerase repeat amplification assay.
MINO cells were dissociated and cultured in three dimensional
culture and transplanted in syngeneic gland cleared mammary
fat pads.
Results Comparative genomic hybridization shows that the
precancer and invasive tumors are genetically stable, with low
level changes including whole chromosome gains in some lines.
No changes are associated with progression, although
spontaneous focal amplifications and deletions were detected
occasionally. Microsatellite analysis shows a low frequency of
alterations that are predominantly permanent within a MINO line.
Telomerase activity is increased in both the MINO and the
derived tumors when compared with normal mouse mammary
gland. Dissociation of the precancer lesion cells and three
dimensional 'spheroid' culture of single cells reveals a
bipotential for myoepithelial and luminal differentiation and the
formation of unique three-dimensional 'MINOspheres'. These
MINOspheres exhibit features that are intermediate between
spheroids that are derived from normal and carcinoma cells.
Transplantation of a single cell derived MINOsphere
recapitulates the outgrowth of the precancer morphology and
progression to carcinoma.
Conclusion These data establish a precancer 'stem' cell that is
capable of self-renewal and multilineage differentiation as the
origin of invasive cancer. Within the context of this model, these
cells have programmed potential for latency and metastasis that
does not appear to require sequential genetic 'hits' for
transformation.
Introduction
Ductal carcinoma in situ (DCIS) refers to phenotypically heter-
ogenous lesions that are defined by a common property –
increased risk for cancer at the site of the biopsy [1-3]. This
property implies a direct clonal progression from DCIS to inva-
sive carcinoma, and it is the conceptual basis for current DCIS
treatment [4]. DCIS can be subtyped and graded with implica-
tions for latency to invasion and the likelihood of spread/recur-
rence [5]. Although controversial, DCIS does not appear to
progress from lower grades or low risk types to higher grades
or higher risk types en route to cancer or upon recurrence,
which suggests a relatively stable population. In summary, the
clinico-epidemiologic pathology data support the hypothesisPage 1 of 13
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phenotype, possibly including progression to invasion, metas-
tasis, hormone receptor expression, and therapeutic resist-
ance.
We have used the combination of mammary transplantation
[6] with derivative genetically engineered mouse mammary
gland to create a mouse model of DCIS that recapitulates the
clinico-epidemiologic observations in human disease [7]. The
models are referred to as mouse mammary intraepithelial neo-
plasia outgrowths (MINOs). The biologic behavior of these tis-
sues is operationally defined by the 'test-by-transplantation', in
which each of the six MINOs meets the following transplanta-
tion criteria: grows in gland-cleared fat pad (orthotopic); does
not grow in the subcutis (ectopic); does not senesce over
many generations of transplantation; and consistently trans-
forms to a phenotype characterized by an ability to grow in the
subcutis (ectopic). Of particular interest and relevance to our
understanding of human breast cancer progression are three
preliminary findings. First, three of the lines metastasize and
three do not. This finding is consistent over subsequent gen-
erations of MINO transplantation [8]. Second, the time or
latency to transformation is consistent within a given MINO
line over multiple transplant generations, although different
lines have different latencies. Third, gene expression analysis
and hierarchical clustering show that a MINO and the trans-
formed lesion arising within it are more closely related than any
two MINO lines or any two transformed tumors [8,9]. Because
the recipient mice are genetically identical but immune-intact
FVB mice, and because the origins of the MINO lines are two
genetically identical transgenic mice, Tg(MMTV-PyVmT) on an
FVB background, this can be considered a model of human
DCIS without variation in genetic susceptibility loci.
These characteristics of the MINO model support the hypoth-
esis of a preprogrammed behavior at the precancer stage. In
this report we show that these potentials are pre-encoded in
individual cells within the complex MINO tissue. This individual
cell precancer reinitiating potential is supported in part by evi-
dence that the precancers and resulting cancers are clonally
derived and telomere stabilized. However, the truest definition
of initiating cell behavior in single precancer cells employs a
functional analysis in vivo. For this MINO model, previously
published data [10] and Additional files presented here show
genetic clonality and genomic stability by medium-resolution
and high-resolution array comparative genomic hybridization
(CGH). Despite the fact that a large number of cell types are
co-transplanted in each generation, the precancer cells and
the tumor cells that arise within the precancer share this
apparent clonal origin.
In this report we also show by telomerase analysis that both
the precancer and invasive carcinomas are characterized by
increased activity, which is sconsistent with the genomic sta-
bility observed in these tissues. We show that rare individual
cells within the MINO tissue are responsible for this clonal but
phenotypically heterogeneous biology. Finally, we show that
the criteria of cancer stem cells (as defined by the American
Association for Cancer Research task force on cancer stem
cells [11]) for self-renewal and the ability to reconstitute the
neoplasm are present in these individual cells. This finding, in
combination with the previously published findings of con-
served latency to invasive carcinoma and conserved meta-
static potential, suggests that the cancer phenotype is
programmed or imprinted in the precancer initiating cell [11].
Materials and methods
Microsatellite PCR
Microsatellite PCR was performed using the NaOH extracted
DNA samples (normal mammary gland, MINO, and cancer tis-
sue) above in multiplexed assays to interrogate loci spread
over the mouse genome. (The panel was originally developed
for mouse strain background analysis.) The primers used were
all from the collection developed at the Massachusetts Insti-
tute of Technology. The following cycling conditions of PCR
were used: 23 cycles of 95°C for 10 minutes, 85°C for 10 min-
utes, and 95°C for 1 minute; 23 cycles of 55°C for 0.5 min-
utes; 23 cycles of 72°C for 0.75 minutes; and 72°C for 30
minutes and then 5°C. PCR products were replicated with
10:2:1 formamide:dye:genscan ladder and then denatured for
3 minutes at 95°C and neutralized for 1 minute at 4°C. The
samples were run on 7% denaturing polyacrylamide gel. Sam-
ple results are shown as nucleotide length performed via ABI
sequencing column analysis (Applied Biosystems, Foster City,
CA, USA). Analysis was performed using STRand software
created by the Veterinary Genetics Laboratory at the Univer-
sity of California, Davis.
Telomerase activity detection
Telomerase activity was evaluated using the TRAPeze Telom-
erase Detection Kit (Chemicon International, Temecula, CA,
USA) using 200 μl of 1×CHAPS lysis buffer/100 mg of MINO
tissue or MINO tumor. Total protein extracts were quantified
using the Bradford assay and diluted in collection buffer
(1×CHAPS) to concentrations of 50 μg/ml, 10 μg/ml, and 2
μg/ml for incubation with the telomere repeat DNA template.
The PCR program used was as follows: 30 to 33 cycles of
94°C for 30 seconds, 59°C for 30 second, and 72°C for 1
minute. We ran 25 μl of this PCR product on a 10% to 12%
nondenaturing PAGE gel in 0.5× TBE buffer, for 1.5 hours at
200 V. Thirty-six base pairs (bp) was used as internal control
for PCR. The gel was stained with ethidium bromide 1:10,000
for 30 minutes and then destained for 30 minutes. The ratio of
band intensity (50 bp:36 bp) was used for quantification, and
the average for this ratio divided by the protein concentration
recorded for each sample reaction.
Single cell isolation and spheroid analyses
Normal, MINO, and tumor tissues were obtained from wild-
type FVB females at 4 weeks after transplantation for MINOPage 2 of 13
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McIlwain tissue chopper (Mickle Laboratory Engineering,
Guildford, UK), the tissues were placed in serum-free diges-
tion medium (F12/Dulbecco's modified Eagle's medium
[DMEM] 1:1 with 10 mmol/l Hepes [Invitrogen, Carlsbad, CA,
USA], 2× P+S, 2% bovine serum albumin fraction V [Invitro-
gen], 5 mg/ml Insulin [Sigma, St Louis, MO, USA], 0.5 mg/ml
hydrocortisone [Sigma], 10 ng/ml cholera toxin [Sigma], and 3
mg/ml Collagenase [Worthington Biochemical Corp., Lake-
wood, NJ, USA] and digested on a stirrer plate for 16 hours at
room temperature. The resulting organoid suspension was
pelleted at 80 g for 4 minutes and sequentially washed with
F12/DMEM and pelleted at 1,000 rpm for 4 minutes. A suspen-
sion of single cells was obtained by sequential dissociation of
the fragments by gentle pipetting and incubation at 37°C for 1
to 2 minutes in 0.25% trypsin. After adding 0.1 mg/ml DNase
I, the sample was incubated for a further 5 minutes at 37°C
and then an equal volume DMEM with 10% fetal calf serum
was added to stop the trypsinization. Remaining clumps were
removed by filtration through a 40 mm cell strainer. For three-
dimensional culture the single cells were pelleted and resus-
pended using cooled pipettes in cold BD Matrigel matrix [BD
Biosciences, Bedford, MA, USA] and plated in 24-well plates.
The plates were incubated at 37 C for 30 minutes and then the
growth medium was added (mammary epithelial growth
medium with 1× B27, 20 ng/ml epidermal growth factor [BD
Biosciences], 20 ng/ml basic fibroblast growth factor [BD Bio-
sciences], heparin, and 20 mg/ml insulin [Sigma]).
After 2 weeks in Matrigel the spheroids arising from single
cells were transplanted or fixed in 10% formalin, embedded
first in HistoGel Biopsy Gel [Richard-Allan Scientific, Kalama-
zoo, MI, USA] and then in paraffin. Transplantations of sphe-
roids were done with the aid of a Zeiss Stemi 2000-C
dissecting microscope (Carl Zeiss Inc., Thornwood, NY,
USA). Spheroids, cultured within Matrigel, were identified and
located with the dissecting microscope. A Dumont #5–45 for-
ceps [Dumoxel-Fine Science Tools Inc, Foster City, CA, USA]
was used to gently hold and lift individual spheroids from the
culture dish. Each MINOsphere(s) was transplanted into the
cleared inguinal fat pad of FVB/N female mice.
Histology and immunohistochemistry
Four micrometer thick paraffin sections were stained with
Mayer's hemotoxylin and eosin or immunostained as
described previously [8]. The following primary antibodies
were used with the VECTASTAIN ABC Elite Kit (Vector Labo-
ratories, Burlingame, CA, USA): guinea pig anti-cytokeratin
(CK) 8–18 (1:1,000; RDI- Research Diagnostics Inc, Con-
cord, MA, USA), sheep anti-CK14 (1:400; Binding Site Inc.,
San Diego, CA, USA), rabbit anti-Ki67 (1:800 Neomarker, Fre-
mont, CA, USA), and rabbit anti-CK5 (1:1,000 Abcam Inc.,
Cambridge, MA, USA). Dako Ark kit (Dako, Carpinteria, CA,
USA) was used for immunohistochemistry with mouse anti-
smooth muscle actin (SMA; 1:1,000; Sigma) antibody. Images
of slides were captured using 20× and 40× objectives on a
AxioScope microscope (Carl Zeiss Inc.) with AxioCam camera
and processed using Adobe Photoshop 7.0 (Adobe Systems,
Inc., San Jose, CA, USA) software.
Results
MINO growth properties
Each of the six individually derived MINO transplant lines main-
tains consistent genomic changes through serial generations
and between recipients within a line and within a transplant
generation. The MINO lines have been maintained in serial
transplantation for between 50 and 60 generations (depend-
ing on the line) without senescence. Considerable phenotypic
heterogeneity exists between lines and within a line. Several
important behaviors have remained consistent, however, and
these define these mammary outgrowths as 'mammary
intraepithelial neoplasia' (MIN) or precancer. Specifically, the
MINO tissues grew only in the cleared fat pad and were con-
tact inhibited by the edge of the pad or by an adjacent mam-
mary tree. As shown in Figure 1, the MINOs grow to fill the
cleared fat pad with a leading edge mimicking normal gland
development, including 'terminal end bud' extensions into the
surrounding fat pad (Figure 1b). Just as in the developing nor-
mal gland, this proliferative and expanding area is character-
ized by proliferation followed by apoptosis and differentiation
leading to a 'differentiation zone' (Figure 1c) in the MINO.
Within this differentiation zone of MINO tissue, invasive carci-
nomas arise (Figure 1d). These are characterized by more
spherical growth, which is not limited to the dimensions of the
fat pad, and by the potential for ectopic growth if transplanted
subcutaneously.
Microsatellite analysis of MINO and tumor
Cancers may harbor genetic instability undetected by karyo-
type or CGH analyses, although human breast cancer is usu-
ally characterized by aneuploidy, abnormal karyotypes, and
abnormal genomic content by CGH. Nevertheless, instability
in some cancers may be comprised of single base mutations
or amplifications or deletions that are too small to be detected
by CGH. A sensitive assay to detect instability unresolved by
CGH is the analysis of microsatellite repeats within the
genome. Dinucleotide repeats are the most sensitive, followed
by trinucleotide and then tetranucleotide repeats. Repeat
length of microsatellites distributed throughout the mouse
genome was determined in multiplexed PCR assays.
The results are summarized in Table 1 and Additional file 1
alongside the CGH results, and complete results are pre-
sented in Additional file 2. Each red filled box in Additional file
1 represents a repeat length different from the normal control.
The number of microsatellite changes is small. Additional file 2
and the data summary presented in Table 1 and in the Addi-
tional file 1 shows line A with only four changes of 192 repeats
tested, with two in common between MINO and tumor and
two unique to the tumor. Line D shows six changes of the 192Page 3 of 13
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paired tumor (five additional changes were uninformative
because of a failed reaction for one of the samples). Line 11
shows seven changes in the MINO and six of them with one
additional in the tumor. Line B shows five changes with one
additional in the tumor. Line 4 shows seven changes in the
MINO with six of the seven present in the tumor.
By criteria for genetic instability phenotypes in human cancers,
these results would be considered genomically 'stable' [12].
Most changes detected were seen in common between the
MINO and the associated invasive carcinoma. For a few loci,
the MINO and tumor did have different changes, but none of
these unique tumor changes were shared between lines.
Changes seen in the tumor and not the MINO might represent
a very low frequency of genetic instability. Changes seen in
MINOs and not tumors imply divergent evolution of the MINO
clone, with the tumor arising from an area in the MINO that did
not harbor the specific change. The majority of changes were
unique to the MINO line, and still present in the invasive tumor
in the line, implying that the invasive tumor arises from cells of
the precancer MINO.
Telomerase activity/telomerase repeat amplification 
protocol assay
In order to evaluate the activity of telomerase in the MINO tis-
sues and matched tumors as compared with normal mammary
epithelium, we performed the telomerase repeat amplification
protocol (TRAP) assay. A sample of the polyacrylamide gel
electrophoresis is shown in Figure 2a. Here the TRAP assay
showed the formation of an extended ladder of six base
repeats but with a quantitative competition between the telom-
erase repeat template and the internal control (36 bp) for PCR.
The ratio of band intensity (50 bp:36 bp) was used for quanti-
fication. The average for this ratio divided by the protein con-
centration was recorded for each sample. The resulting
representation of quantitative data is shown in Figure 2b. This
histogram shows a consistently higher telomerase activity in
MINO and tumor tissues compared with normal tissue. Signif-
icant variability between samples was observed. Some lanes
were considered 'failed reactions' and were discarded. The
variability contributes to the size of the error bars, but in all
cases, except for the line B MINO, the error does not overlap
with normal. The data also present a higher average telomer-
ase activity in tumors relative to the MINOs in which they
arose, but this is not statistically significant. This trend may be
related to an increased contribution from normal stroma in the
MINO tissue compared with the tumor tissue samples. In many
studies the subjective analysis of ladder intensity and height
(repeat length) was more clearly increased from normal than
indicated by the quantitative ratio, but this subjective analysis
(as illustrated in Figure 2a) was not quantified. Notably, con-
sistent with the literature, the normal mouse mammary gland
Figure 1
Histomorphology of the MINO model mammary precancer with early invasive carcinoma. (a) Low-power hematoxylin and eosin histomorphology of 
the MINO precancer filling the precleared fat pad. Intact gland is seen for comparison in the bottom left corner. The lymph node is seen (LN) at the 
left, and no invasion of the node by precancer tissue is seen. (b) The edge of the precancer is seen at higher power and is similar to a normal devel-
oping mammary gland terminal end bud with mitoses (arrowhead) and remodeling via apoptosis to clear the luminal space. In the area of precancer 
in the center of the growth there is an organized relationship between the transplanted MINO tissue and the host stroma. (c) The MINO cells differ-
entiate to form acinar and ductal structures with high intralesional cell heterogeneity. (d) In this heterogeneous differentiated zone of precancer tis-
sue, an area of transformation to invasive carcinoma is characterized by increased mitoses (arrowheads) and much less residual host stromal tissue. 
MINO, mammary intraepithelial neoplasia outgrowth.Page 4 of 13
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Table 1
Summary of CGH BAC array and multiplexed microsatellite PCR length changes in the MINO precancer tissue and paired invasive 
carcinoma
Line designation/G0 generation # Generation G0 Generation G0+1
MINO Paired tumor MINO Paired tumor
Line A CGH whole 
chromosome
+ch13WC Same → Same → Same +ch11WC
G0 = 12th CGH locus changes +ch5BAC1 Same → Same +ch5BAC2 → Same
MS d5–95; d7–253 → Same +d6–123; 
d9–90
(Replicate animal) CGH whole 
chromosome  Same  Same +ch11WC
CGH locus changes Normal Normal
Line D CGH Normal Normal
G0 = 12th MS d1–24; d2–149; d4–178; 
d12–109; d12–182; 
d14–170
→ Same less d1–24; plus 
d7–165
Line 11 CGH whole 
chromosome
Normal Normal
G0 = 11th CGH locus changes Normal +ch5distalG1:G3 (17 
BACs); +ch11BACs3–5
MS d2–149; d4–166; 
d5–113; d8–205; 
d11–61; d16–131; 
d18–19
→ Same less d2–149; plus 
d9–182
Line B CGH +ch1WC, +ch2WC, 
+10WC, +11WC,
→ Same less +ch11WC, 
plus +ch15WC
G0 = 14th +ch3BAC6, +ch17BAC7 → Same plus +ch5BAC1, 
+ch5BAC2, del ch7BAC8, 
del ch8BAC9, del 
ch10BAC10
MS d6–138, d8–93, d8–120, 
d10–14, d11–61
→ Same +d17–93
Line 4 CGH whole 
chromosomes
+ch1WC +ch2WC +ch2WC → Same
G0 = 13th CGH locus changes +ch5BAC1, +ch6BAC11 → Same less ch6BAC11 Normal del-ch2BAC12, del-
ch6BACBAC13, del-
ch18BAC14, del-
ch18BAC15
MS d1–102, d2–149, 
d12–109, d12–182, 
d12-nds, d15–175, 
d3–57
→ Same less d2–149
Line 6 CGH whole 
chromosome
Normal Normal +ch1WC → Same
G0 = 11th CGH locus changes Normal Normal +distal ch5G1:G3 (18 
BACs), +ch3BAC2
→ Same
(Replicate animal) CGH whole 
chromosome
Normal Normal
CGH locus changes Normal Normal
The initial serial transplant generation (G0) tested is given for each line, and, for several lines, a successive generation (G0+1) was tested. Replicate animals 
transplanted at the same time from the same donor (previous generation) were also tested. The changes from normal are listed as comparative genomic hybridization 
(CGH) detected whole chromosome (WC) gains (+ch#), CGH focal locus amplifications (+) and deletions (del). The bacterial artificial chromosome (BAC) clones are 
numbered as follows: BAC1 = RP23 422O10; BAC2 = RP23 93M18; BAC3 = RP23 276J22; BAC4 = RP23 295O13; BAC5 = P1–7858; BAC6 = RP23 233B21; 
BAC7 = RP23 193I17; BAC8 = RP23 413L18; BAC9 = RP23 23D17; BAC10 = RP23 421E11; BAC11 = RP23 127M17; BAC12 = RP23 129L11; BAC13 = 
RP23 393H9; BAC14 = RP23 27B11; and BAC15 = RP23 35M16. Most of the BACs are from Roswell Park (RP) 23 collection. Also shown are microsatellite (MS) 
changes compared with normal control (MSs were not tested for line 6). Specifics of MS changes are available in Additional file 2. The arrows indicate comparisons 
with samples either from a previous generation or from the MINO preceding the invasive cancer (→) or from a different transplant in the same generation listed in rows 
above ( ). MINO, mammary intraepithelial neoplasia outgrowth.
? ?
?
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tissues.
Cell dissociations and organoid culture
Because the serial transplant tissues are composed of multi-
ple cell types, the precancer outgrowths are not precisely a
clonal derivative of a single cell. In order to overcome this
objection, we initially attempted to grow the precancer cells in
adherent cell culture using the techniques previously
described for mouse mammary carcinoma cell line derivations
[13]. This resulted in either poorly growing cultures or cultures
of cells that, after serial passage, acquired characteristics of
invasive carcinomas/tumors. Specifically, they acquired the
ability to grow in ectopic locations (subcutaneous). In con-
trast, cell dissociations of MINO tissues and injection of these
cells or mammospheres grown in suspensions from these
cells into the precleared fat pad resulted in MINO phenotypes,
which did not grow in subcutaneous/ectopic sites. Thus, con-
version of the precancer to invasive carcinoma was not related
to cell dissociation alone.
Therefore, three-dimensional culture techniques were adapted
and optimized. Several initial considerations were critical to
the experiments. First, MINO tissues for cell dissociations and
culture were harvested early enough to ensure that no nascent
tumors were present in the precancers, using in situ micro-
Figure 2
Telomerase activity of MINO and tumor tissues. Telomerase activity by telomerase repeat amplification protocol (TRAP) assay. Representative ethid-
ium stained polyacrylamide gel electrophoresis of the PCR products resulting from protein extract incubation with artificial telomere repeat template 
showing a bright 50 bp band with 6 bp increasing length ladder. At the bottom of the gel is a 36 bp internal PCR control, with PCR optimized to be 
semi-competitive with the extended telomere repeats produced by the telomerase protein derived from each sample. The protein samples are diluted 
in buffer and then added to the reaction mixture to provide a final reaction mixture concentration as listed (top of each lane). Matched MINO and 
tumor samples were tested. (a) Lines 4w4 and 4w11 are shown, with normal mouse mammary epithelium control (separated from the stroma by par-
tial tissue dissociation and centrifugation) shown in the right three lanes. (b) Quantitation by comparing the band intensity with the internal control for 
multiple samples is shown, with standard deviation of the mean depicted for each bar. Line 11 tumor had the highest levels, at a mean of 500 (not 
shown), and all samples except for line B MINO were statistically significantly different from the normal control. There was a high level of variability 
between assay runs, depicted by the size of the error bars, but the qualitative data were clear, as shown in the gel (panel a). bp, base pairs; MINO, 
mammary intraepithelial neoplasia outgrowth; TRAP, telomerase repeat amplification protocol.Page 6 of 13
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course study and in vivo imaging [8,14]. Although the latency
time varies for each line, MINO tissues were generally har-
vested before 5 weeks for all dissociation studies. Second,
after serial cell dilutions, the cells were plated in an artificial
extracellular matrix (Matrigel) to prevent individual cells from
contacting or 'bumping into' each other, sticking, and cooper-
ating in their subsequent growth. This permitted assessment
of the potential for growth and morphology of individual cells.
Because of the importance of the potential of each individual
cell, the rate of doublet and groups of cells persisting through
the dissociations was assessed. In addition, doublet and
groups of cells in the matrix-immobilized cultures were marked
and followed over time to compare their fate with that of the
predominant single cells. These two approaches allowed
assessment of the growth properties of single isolated cells.
Three-dimensional cultures of MINO derived by cell dissocia-
tion were performed in parallel with dissociated cells from nor-
mal (either virgin or pregnant) mouse mammary gland tissue
and with invasive mammary tumor tissue.
A minority of single cells in each group gave rise to three-
dimensional growths in culture. In the normal mammary gland
controls, about 1% to 9% of cells gave rise to small spheroids
that grew in size gradually but retained a spherical shape
(spheroids), with a hollow center appearing after the sphere
reached a sufficient size for identification (Figure 3a). The mor-
phology of the spheroids and the percentage of cells that are
capable of this growth were unchanged between virgin (multi-
ple glands used from multiple mice) and prelactating normal
mammary gland cells. Histologic sections of these normal
spheroids revealed a clear double layer of cells with uniform,
larger luminal mammary epithelial cells lining the center of a
hollow cavity, surrounded by a second layer of flatter cells with
smaller nuclei forming a discontinuous web.
Immunohistochemistry confirmed the cell types with CK8–18
marking the inner luminal cells and CK14 marking the outer
basal cells (Figure 3b–c).
Approximately 1 in 10 isolated single tumor cells gave rise to
a variety of morphologic shapes in the three-dimensional cul-
ture. Irregular and roughly spherical shapes were observed,
but organized central cavities were not (Figure 3g). In the his-
tologic sections the tumors formed irregular aggregates, with
small groups of cells sometimes forming gland-like lumina.
Immunohistochemistry showed both luminal CK8–18 positive
and basal CK14 positive cell types in the tumor organoids
(Figure 3h–i).
In contrast, single MINO isolated cells in three-dimensional
cultures formed three-dimensional growths from roughly
0.08% ± 0.02% of cells. These 'MINOspheres' grew faster
than the normal cell spheroids and had a similar appearance,
with a prominent cavity forming in the center of a spherical
growth (Figure 3d). However, the MINOspheres were charac-
terized by a polarized aggregate of more irregular cell growth,
which was not seen in the spheroids from normal mammary
gland. Histologic assessment of the 'MINOspheres' revealed
an intermediate phenotype between normal and tumor. They
had organized two-cell layer spheres with larger lumina that
account for the greater part of the volume of the growth. Fur-
thermore, one pole of the spheroid contained an irregular
tumor-like growth, which was continuous with the edge of the
spheroid. Immunohistochemistry confirmed that the sphere
was comprised of inner luminal CK18-positive epithelial cells,
surrounded by a more discontinuous outer layer of CK14-pos-
itive myoepithelial cells (Figure 3e–f). The irregular pole was
composed of a more disorganized mixture of luminal epithelial
and myoepithelial cells. Additional immunohistochemistry
(Ki67) demonstrated increased proliferation in the disorgan-
ized region (data not shown).
The MINOsphere phenotype was consistent through multiple
iterations of the experiment and was consistent between dif-
ferent lines of MINO. In particular, lines 4, D, and B were stud-
ied over three independent serial generations. All showed the
MINOsphere phenotype intermediate between normal and
tumor cells. Some differences were observed between MINO-
spheres from different lines. The clearest example of pheno-
typic differences was exhibited by MINO line B. Line B single
cells formed MINOspheres with the area of disorganized cells,
but the spheres became filled with inspissated proteinaceous
debris (not shown).
Transplantation of single cell derived MINOspheres
The MINOspheres resulting from three dimensional cultures in
24-well plates were transplanted in precleared fat pads of syn-
geneic mice. Often, only one MINOsphere per well was
observed in wells plated with 10,000, 5,000, or 1,000 cells.
Under direct observation with a Zeiss dissecting microscope,
the single MINOsphere could be removed from the well and
transplanted into the precleared fat pads of syngeneic 3-week-
old female FVB/n mice. As a control, a similar area of matrigel
but from a well without any apparent MINOspheres was sepa-
rately transplanted. Fifty-five percent (n = 20) of MINOsphere
transplants resulted in MINO growth in the precleared fat pad,
whereas no growth (0%, n = 4) was seen with transplants of
the controls. A two-sided χ2 test of these data results in P =
0.046. The MINOsphere derived outgrowth morphologically
matched the original MINO tissue outgrowth (Figures 1 and
3k).
Importantly, the MINOsphere transplants retained the behavio-
ral properties of terminal end bud-like growth to fill the fat pad,
followed by heterogeneous differentiation and focal transfor-
mation into invasive carcinoma (Figure 3j, arrow). The latency
time to the invasive carcinoma was similar to the previouslyPage 7 of 13
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been retested.
Comparative pathology of MINOsphere derived and 
donor serial tissue transplant outgrowths
The phenotypes of MINOsphere derived outhgrowths
matched the original (donor serial transplant) outgrowths in
comparative pathology analysis. This comparison was also val-
idated by immunohistochemistry. The immunohistochemistry
analyses confirm the same patterns and distributions of
expression of CK8–18, CK5, CK14, and SMA. Ki67 and acti-
vated caspase 3 immunohistochemistry also showed match-
ing proliferation and apoptotic rates (Figure 4). Ki67
quantification in the proliferation zone revealed a comparable
proliferation percentage in donor samples (64.1% ± 20%) and
MINOsphere derived outhgrowths (62% ± 28%). As
expected, some histologic pattern variation between different
MINO lines was observed, and the variation matched patterns
characteristic of each line. A sample comparison of the pheno-
type of derivative donor MINO line and the single cell trans-
plant for MINO line 4 is illustrated in Figure 4. Additionally,
second and third serial transplantations from the single cell
MINOsphere-derived outgrowths retained their characteristic
morphologies (Additional file 3).
Figure 3
Three-dimensional culture of single cells from normal prelactating mammary gland, MINO precancer, and invasive carcinoma. (a, d, g) Inverted 
microscope phase contrast images as well as histologic images generated from paraffin-embedded 4 μm sections of the three-dimensional cultures 
stained by immunohistochemistry with (b, e, h) CK8–18 or (c, f, i) CK14 are shown. The magnification scale (lower right panel i) is identical for all 
histology panels and approximate for the inverted microscopy photographs. CK8–18 confirms that the major cell population is a luminal phenotype, 
but CK14 shows that there is also myoepithelial differentiation of single cells, documenting bipotential of the individual cells giving rise to these 
three-dimensional structures. A single MINOsphere from line 4w4 was transplanted from the three dimensional culture into the gland cleared fat pad 
of a 3-week-old female FVB/n mouse. The mammary gland was removed 10 weeks after transplant and a whole mount mammary gland preparation 
was made with hematoxylin stain to visualize cell density (j). After photography, the same gland was processed for histologic sectioning, and the 
resulting 4 μm hematoxylin and eosin stained tissue section is shown (k). At least three foci of tumor are seen in the differentiation zone of the MINO. 
One is indicated by the arrow. CK, cytokeratin; MINO, mammary intraepithelial neoplasia outgrowth.Page 8 of 13
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The model of breast cancer progression via sequential acqui-
sition of selectively advantageous molecular alterations with
morphologically recognizable phenotypes is a convenient con-
ceptual framework (Figure 5a). However, alternative models
are possible. Progression from one lesion to the next cannot
be experimentally tested in human populations, although sev-
eral associations are clear. DCIS is associated with invasive
cancer in close anatomic proximity. However, progression of
DCIS through sequential grades and progression of invasive
cancer from low to high grade or from estrogen receptor pos-
itive to negative is not common in patient pathology studies.
Purported precursor lesions of hyperplasia and atypical hyper-
plasia are not known to carry higher risks for cancer at the site
of the lesion. Instead, they are markers of risk throughout the
breast. Although there is molecular evidence of clonal relation-
ship between some of these lesions and associated cancer,
the same analysis shows clonality with 'normal' mammary epi-
thelium. Finally, the specific 'hits' that are responsible for the
transition from DCIS to invasive cancer remain elusive despite
extensive study.
The model proposed by Chin and colleagues [15] describes
the initiation of cancer occurring through telomere shortening
and genetic instability, with a pattern of genetic changes
becoming stabilized in the cell that reactivates telomerase
Figure 4
Immunohistochemistry profile of MINOsphere-derived outgrowth versus the original MINO tissue outgrowth. The outgrowth derived from a MINO-
sphere transplant (a, c, e, g, i, k) shows analogous expression compared with the MINO tissue outgrowth from the donor (b, d, f, h, j, m) for the fol-
lowing: luminal epithelial, CK8–18 (panels a and b); basal epithelial/myoepithelial, CK14 (panels c and d) and CK5 (panels g and h); myoepithelial/
smooth muscle, SMA (panels e and f insets show higher magnification of SMA-positive cells within the epithelial layers); and proliferation/apoptosis, 
Ki67 (panels I and j)/caspase3 (panels k and l). Panels a to h are of identical magnification, with the 200 μm scale bar shown (panel h). Panels i to l 
are identical magnification with the 100 μm scale bar shown (panel l). CK, cytokeratin; MINO, mammary intraepithelial neoplasia outgrowth; SMA, 
smooth muscle actin.Page 9 of 13
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genetic composition might be considered the 'birth' of the can-
cer-initiating cell [11]. Quite remarkably, their model suggests
that this occurs as the tissue becomes DCIS. That is to say,
the cancer stem cell [11] is 'born' at the precancer stage. Our
data modify the model slightly, to show that genetic instability
is not required in this process. Over-expression of a single
transgene is sufficient in our genetically engineered model
system. Similarly, however, the MINO model suggests that the
immortalization results in the 'birth' of a precancer stem cell
and that there is a stabilized programming of this cell [11]. Our
data support a modified model, in which the programming sta-
bilized in the precancer stem cell might be epigenetic as well
as genetic. Also, ongoing genetic 'low level' changes and epi-
genetic changes may or may not contribute heterogeneity, but
are not required for progression (Figure 5c).
Others have proposed that cancer with specific properties
may arise in parallel rather than sequentially from the histomor-
phologic lesions associated with cancer risk. Mathematic
modeling, supported by gene expression correlative data,
demonstrates a high probability for this model in human can-
cer progression [16,17]. Our results are the first to document
this parallel progression model experimentally. Specifically, we
show that mammary precancer harbors individual cells that are
capable of reconstituting the precancer tissue, and that these
cells have a stable, programmed malignant potential that does
not depend on sequential acquisition of genetic alterations.
Each of the precancer lines is derived from genetically identi-
cal mammary tissue but develop divergently. The divergent
lines, derived from biopsy transplantation, harbor unique and
consistent malignant transition latencies and metastatic
capacity. These findings confirm a precancer 'stem' cell, as
defined by the AACR working group [11], as the origin of inva-
Figure 5
Conceptual models of breast cancer progression. (a) Sequential acquisition of molecular alterations with selection of advantageous 'hits' and corre-
sponding morphologic progression (modified from Burstein and coworkers [4]). Individual 'hits' are depicted with small 'lightening bolts'. (b) Hyper-
plasia results in shortening telomeres, rapidly increasing genetic instability during 'telomere crisis', and relative stability after telomerase reactivation 
(modified from Chin and coworkers [15]). Individual cells reactivating telomerase and with a 'fit' genetic profile give rise to the carcinoma in situ 
(DCIS) and then the invasive carcinoma. (c) Genetically stable precancer stem cells are initiated via oncogene activation with divergent behavior 
programmed via epigenetic encoding and possible but not required genetic content changes. Intermediate morphologic and molecular events are 
not required for progression. These cells give rise to the DCIS and have an innate latency to invasive carcinoma and an innate metastatic potential.Page 10 of 13
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sequential acquisition of selectively advantageous traits
through genetic 'hits'. Instead, the data support a divergent
evolution of precancer stem cells with intrinsic programmed
latency to invasion and metastatic potential.
Because human breast cancer progression has been associ-
ated with genetic instability, we initially hypothesized that we
would find genetic changes related to precancer-to-carcinoma
progression in the MINOs, either common to several of the
lines or consistently found within a single line. This would also
correlate with data from another mouse model of DCIS, p53-
null mammary epithelial transplant, which exhibits genetic
instability and heterogeneous progression to a spectrum of
carcinomas [18,19]. Instead, in our model, we found no con-
sistent CGH changes in the transition from precancer mam-
mary intraepithelial neoplasia to invasive carcinoma. In fact,
most invasive carcinomas were nearly identical in their
genomic content to the paired MIN precancer [10] (and Addi-
tional file 1). Specifically, several of the lines exhibited a normal
CGH profile, suggesting a euploid and unaltered genomic
content. In others, there were few changes and most were
whole chromosome gains. In addition, CGH analyses
detected differences between the six independently derived
and maintained lines of MINO. Changes seen in each line were
consistent between separate animals within a transplant gen-
eration and from one generation to the next, with up to three
serial transplant generations studied. Furthermore, there are
no changes in common between lines or related to progres-
sion from MINO to tumor. Therefore, the genomic changes are
perhaps best regarded as markers of clonal cell populations
rather than mechanistically important genetic changes. Taken
together, these CGH profiles indicate that the individual MINO
lines harbor stable genomic changes consistent with a com-
mon origin (clonality).
The 'telomere crisis' hypothesis [15,20] is supported, in part,
by our studies. Despite the absence of high levels of genetic
instability in our model system, telomerase activity and restabi-
lizaton at the inception of the precancer is confirmed. The dif-
ferences between telomerase activity in our MINO model and
human tissue may be related in part to species differences. In
fact, mouse cells have longer telomeres than human cells, and
are less susceptible to genetic instability caused by telomere
shortening [21]. Nevertheless, normal mouse mammary tissue
will senesce after serial passage [22], and this is probably
related to telomere shortening [23]. Hyperplastic lesions in the
mouse mammary gland that do not senesce after many serial
passages have been identified. Some of these lesions never
progress to invasive carcinoma, but others do progress, and
this defines them as 'precancers' [8]. Because immortalized
hyperplasia as well as true precancers may have stabilized tel-
omeres, this property is not sufficient for cancer initiation. In
the MINO model, the initiating stimulus is provided by the
transgene PyVmT (polyoma virus middle T). Interestingly, how-
ever, PyVmT alone is not sufficient for immediate transforma-
tion to cancer. The intermediate MIN outgrowths express
PyVmT at levels equal to the carcinomas [7]. So, the combina-
tion of PyVmT expression and telomere stabilization is suffi-
cient for establishment of the precancer, but transformation to
cancer requires additional factors that are preprogrammed at
the point of precancer initiation, and not spontaneous 'hits' in
a susceptible tissue/cell.
A great deal of interest has recently been focused on identify-
ing the cancer 'stem' cell [11] in a wide variety of cancers [24].
Attention has emphasized markers identifying the cells with
self-renewal and tumor-reinitiating capacities. These studies
require proof of capacity using a functional assay, usually
tumor growth in xenograft transplants. Here, we present a
refined functional assay similar to findings reported for normal
mouse mammary stem cells by using cleared mammary fat pad
transplantation [25]. Normal, hyperplastic, and precancerous
mammary tissues grow only in this context, whereas cancers
will also grow in ectopic sites [7]. The use of immune intact
syngeneic recipient mice also contributes to a more realistic
model of cancer progression [13]. The refined functional
assay and the use of a highly characterized, well validated
mouse model of cancer progression permits a precise assess-
ment of the earliest origins of these interesting cells.
The importance of the stroma or cell niche is well documented
in epithelial neoplasia [26,27]. In this study we have utilized
two highly specialized stromal environments in the functional
analysis of cell potential: the cleared mammary fat pad and
Matrigel in organoid cell culture. The addition of Matrigel in the
non-adherent culture was adopted primarily for technical rea-
sons to ensure that individual cells were prevented from con-
tacting one another and to facilitate transplantation of single
cell derived organoids. Matrigel is well known to have specific
growth and differentiation inducing effects, however, and may
have had specific effects on susceptible cells in our dissocia-
tions. Although we have transplanted MINO cells directly into
the cleared fat pad many times, they have always been trans-
planted as tissue biopsies [7,8,10,14]. Some of the array of
cell types transplanted in this way may contribute to condition-
ing the stroma for growth of the reinitiating cells, and Matrigel
may be providing a similar condition. Furthermore, the experi-
mental stochiometery may result in an underestimate of the
rate of initiating cell potential. Regardless of the requirement
for specific stroma conditions, these data prove that a single
cell can reinitiate the precancer and maintain the programmed
transformation to cancer.
Conclusion
The experiments described here demonstrate that the precan-
cerous MINO is the product of a genetically stable precancer
initiating cell. These experiments are consistent with the
hypothesis that the full biological potential of cancer is pre-
encoded by the time that a microscopic precancer (DCIS) isPage 11 of 13
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phenomena and that gross genomic change may play a role in
programming but is not necessary for neoplastic progression
to malignancy and metastasis. Our model suggests that the
risk for advancing to invasive breast cancer from human DCIS
will be predictable at the precancer stage, perhaps requiring
an understanding of the interactions between the DCIS epi-
thelium and stroma.
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Additional files
The following Additional files are available online:
Additional file 1
A tif file summarizing CGH and microsatellite analysis by 
line. For each line, samples of MINO and the matched 
tumor were analyzed by BAC array CGH and multiplexed 
PCR for microsatellite changes. For CGH results, 
changes that were seen in all of the MINO or tumor 
samples from each line are depicted in solid color, and 
changes seen in less than 100% of samples in cross-
hatched color with the fraction and total number given 
below. Whole chromosome gains (WCGs) are shown as 
rectangular boxes, whereas smaller amplifications are 
depicted as ovals with (+) symbols and deletions as 
ovals with (-) symbols. The approximate relative 
chromosomal location is mapped with the chromosomes 
depicted along the left edge. The microsatellites are 
depicted as small boxes, with two at each position 
depicting the two alleles. Empty squares are 
microsatellites matching the normal control sample (wild-
type FVB/n) and filled squares are changes in 
microsatellite length from normal. In most cases, the 
length change was seen in one of the two alleles, but in 
a few areas both alleles were altered as in MINO line 
8wD at centromeric chromosome 2 (top of chromosome 
2 as depicted) where both squares are filled. **Line 4w6 
was not studied by microsatellite analysis.
See http://www.biomedcentral.com/content/
supplementary/bcr2104-S1.tiff
Additional file 2
An Excel file showing a microsatellite analysis of MINO 
and matched tumor. Listed are all microsatellite PCR 
nucleotide length results. Open cells indicate failed or 
unreadable reactions.
See http://www.biomedcentral.com/content/
supplementary/bcr2104-S2.xlsPage 12 of 13
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Additional file 3
A tif file showing serial transplantation of MINOSphere-
derived outgrowth. Histology (hematoxylin and eosin 
stained, formalin-fixed, paraffin-embedded 4 μm 
sections) of donor (A, D), second (B, E), and third (C, F) 
serial transplantations from the single cell MINOsphere 
derived outgrowths from MINO line D (panels A, B, and 
C) and MINO line 4 (panels D, E, and F). Line D (panels 
A, B, and C) all show a microacinar pattern and 
transplant attempts resulted in growth of 75% (n = 8) of 
second serial and 100% (n = 16) of third serial 
transplant attempts. MINO line 4 (panels d, e, and f) 
shows a solid lobulated pattern typical of line 4 and 
transplant attempts resulted in growth of 67% (n = 6) 
and 100% (n = 8) of third serial transplants. All panels 
are identical magnification, with the 50 μm scale bar 
shown (panel f).
See http://www.biomedcentral.com/content/
supplementary/bcr2104-S3.tiff
Additional file 4
A Word document outlining the CGH procedure.
See http://www.biomedcentral.com/content/
supplementary/bcr2104-S4.docPage 13 of 13
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